Recipharm has signed and closed an agreement with SERB SA (“SERB”) on a divestment of its rights to its potassium iodide product ThyroSafe® except for the US territory.    The value of the deal is EUR 9.5 million, with EUR 5.9 million paid upon closing and EUR 3.6 million later, conditional upon reaching certain product development milestones. SERB will according to the agreement have an option to acquire the US rights at a later stage.   SERB has in parallel entered into a long te...